Af­ter an up-and-down year, Nek­tar watch­es de­vel­op­ment head Wei Lin walk away as it pur­sues pipeline re­bound

More than any oth­er year in re­cent mem­o­ry, 2020 was a roller­coast­er of highs and lows —most­ly lows. Just ask San Fran­cis­co’s Nek­tar: De­spite ditch­ing its opi­oid pro­gram in Jan­u­ary and of­fload­ing roy­al­ties to its two US-mar­ket­ed meds, the biotech still has hopes for its pipeline to hit a re­bound this year.

But that re­bound won’t hap­pen un­der the watch of se­nior VP and head of de­vel­op­ment Wei Lin, who is step­ping down and leav­ing im­munol­o­gy head Bri­an Kotzin to step in.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER